All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F11%3A00002516" target="_blank" >RIV/00023001:_____/11:00002516 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.2215/CJN.00270111" target="_blank" >http://dx.doi.org/10.2215/CJN.00270111</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.2215/CJN.00270111" target="_blank" >10.2215/CJN.00270111</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes

  • Original language description

    Background and objectives Renal transplant recipients with pre-existing diabetes (PD) have reduced graft survival and increased risk of mortality and ischemic heart disease compared with nondiabetic transplant recipients. To assess the effect of belatacept in this high-risk group, we evaluated outcomes of the subpopulation with PD from previously published BENEFIT and BENEFIT-EXT trials. Design, setting, participants, & measurements A post hoc analysis evaluated pooled data from BENEFIT (living donors or standard criteria donors) and BENEFIT-EXT (extended criteria donors). Patients were randomized to receive cyclosporine or a more intensive (MI) or less intensive (LI) belatacept regimen. Results Of 1209 intent-to-treat patients, 336 had PD. At 12 months, the belatacept LI arm demonstrated a numerically higher rate of patients surviving with a functioning graft (90.4% MI [103 of 114], 92.8% LI [90 of 971, and 80.8% cyclosporine [101 of 125]), and fewer serious adverse events than cyclos

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FE - Other fields of internal medicine

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2011

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Clinical journal of the American Society of Nephrology

  • ISSN

    1555-9041

  • e-ISSN

  • Volume of the periodical

    6

  • Issue of the periodical within the volume

    11

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    9

  • Pages from-to

    2696-2704

  • UT code for WoS article

    000296821300022

  • EID of the result in the Scopus database